NEW YORK (GenomeWeb News) — Lumera yesterday said first-quarter revenues increased 71 percent as R&D spending fell 20 percent and net loss narrowed 15 percent.
 
Total receipts for the three months ended March 31 increased to $860,000 from $503,000 million year over year.
 
Lumera also said it had just over $2 million in backlogged government contracts at the end of the quarter.
 
R&D spending dipped to $1.3 million from $1.6 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.